title: Recent Progress in Triple Negative Breast Cancer Research.
abstract: Triple-negative breast cancer (TNBC) is defined as a type of breast carcinoma that is negative for expression of oestrogene and progesterone hormone receptors (ER, PR) and HER2. This form of breast cancer is marked by its aggressiveness, low survival rate and lack of specific therapies. Recently, important molecular characteristics of TNBC have been highlighted and led to the identification of some biomarkers that could be used in diagnosis, as therapeutic targets or to assess the prognosis. In this review, we summarize recent progress in TNBC research focusing on the genetic and epigenetic alterations of TNBC and the potential use of these biomarkers in the targeted therapy for better management of TNBC.
authors.affiliation: Equipe deRecherche ONCOGYMA, University of Mohamed V, Faculty of Medicine and Pharmacy of Rabat Morocco E-mail : m.amrani@um5s.net.ma.
authors.forename: Fatima Zahra
authors.initials: FZ
authors.lastname: Mouh
authors.forename: Mohammed El
authors.initials: ME
authors.lastname: Mzibri
authors.forename: Meriem
authors.initials: M
authors.lastname: Slaoui
authors.forename: Mariam
authors.initials: M
authors.lastname: Amrani
mesh_terms: D014408:Biomarkers, Tumor / Q000378:metabolism*; D005260:Female; D006801:Humans; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D064726:Triple Negative Breast Neoplasms / Q000175:diagnosis / Q000378:metabolism / Q000628:therapy*
chemical_list: D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone